Bosutinib
Information
- Drug Name
- Bosutinib
- Description
- Entry(CIViC)
- 50
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| chronic myeloid leukemia |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Supports
|
Reduced Sensitivity | Somatic | 2 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Tyr272Phe (p.Y272F) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272Phe (p.Y272F) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | C |
Predictive
|
Supports
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | C |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 22371878 | Detail |
| chronic myeloid leukemia | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | C |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | C |
Predictive
|
Supports
|
Reduced Sensitivity | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Supports
|
Reduced Sensitivity | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Supports
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 p.Phe505Ser (p.F505S) ABL1 p.Phe505Ser (p.F505S) | C |
Predictive
|
Supports
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Supports
|
Reduced Sensitivity | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Leu317Val (p.L317V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu317Val (p.L317V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Phe330Ile (p.F330I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe330Ile (p.F330I) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu472Gln (p.E472Q) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Gln (p.E472Q) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Supports
|
Reduced Sensitivity | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Gln319Arg (p.Q319R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln319Arg (p.Q319R) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Phe330Leu (p.F330L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe330Leu (p.F330L) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Asn350Ser (p.N350S) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asn350Ser (p.N350S) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Leu383Pro (p.L383P) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu383Pro (p.L383P) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Supports
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Asp440Gly (p.D440G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp440Gly (p.D440G) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu469Val (p.E469V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu469Val (p.E469V) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu472Lys (p.E472K) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Lys (p.E472K) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Glu472Ala (p.E472A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Ala (p.E472A) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Pro499Ala (p.P499A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Pro499Ala (p.P499A) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 21865346 | Detail |
| chronic myeloid leukemia |
ABL1 p.Cys494ValfsTer8 (p.C494Vfs*8) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Cys494ValfsTer8 (p.C494Vfs*8) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia |
ABL1 p.Asn355Ser (p.N355S) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asn355Ser (p.N355S) ( ENST00000318560.6, ENST00000372348.9 ) |
C |
Predictive
|
Does Not Support
|
Resistance | Somatic | 1 | 22371878 | Detail |
| chronic myeloid leukemia | ABL1 MUTATION ABL1 MUTATION | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 21865346 | Detail |
| chronic myeloid leukemia | ABL1 MUTATION ABL1 MUTATION | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 22371878 | Detail |
| chronic myeloid leukemia | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 2 | 22371878 | Detail |
| chronic myeloid leukemia | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 22371878 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Tyr272Phe (p.Y272F) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272Phe (p.Y272F) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | N/A | true | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 p.Phe505Ser (p.F505S) ABL1 p.Phe505Ser (p.F505S) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Leu317Val (p.L317V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu317Val (p.L317V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Phe330Ile (p.F330I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe330Ile (p.F330I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Glu472Gln (p.E472Q) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Gln (p.E472Q) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Gln319Arg (p.Q319R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln319Arg (p.Q319R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Phe330Leu (p.F330L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe330Leu (p.F330L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Asn350Ser (p.N350S) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asn350Ser (p.N350S) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Leu383Pro (p.L383P) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu383Pro (p.L383P) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Asp440Gly (p.D440G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp440Gly (p.D440G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Glu469Val (p.E469V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu469Val (p.E469V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Glu472Lys (p.E472K) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Lys (p.E472K) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Glu472Ala (p.E472A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Ala (p.E472A) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 |
ABL1 p.Pro499Ala (p.P499A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Pro499Ala (p.P499A) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Cys494ValfsTer8 (p.C494Vfs*8) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Cys494ValfsTer8 (p.C494Vfs*8) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 |
ABL1 p.Asn355Ser (p.N355S) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asn355Ser (p.N355S) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 | ABL1 MUTATION ABL1 MUTATION | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this retrospective study, imatinib-resistant or... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 MUTATION ABL1 MUTATION | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective study of dasatinib and/or... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Bosutinib is a SRC inhibitor | SRC | SRC EXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04578847 | Active, not recruiting | Phase 2 | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | January 15, 2020 | January 15, 2025 |
| NCT03854903 | Active, not recruiting | Phase 1 | WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor | April 1, 2019 | November 1, 2025 |
| NCT04971226 | Active, not recruiting | Phase 3 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | October 6, 2021 | January 18, 2028 |
| NCT03654768 | Active, not recruiting | Phase 2 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | October 24, 2018 | July 1, 2028 |
| NCT04258943 | Active, not recruiting | Phase 1/Phase 2 | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia | April 6, 2020 | July 2028 |
| NCT03106779 | Active, not recruiting | Phase 3 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | November 29, 2016 | December 18, 2024 |
| NCT00952913 | Completed | Phase 1 | Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects | August 2009 | October 2009 |
| NCT00195260 | Completed | Phase 1 | Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors | October 2004 | November 2007 |
| NCT01233882 | Completed | Phase 1 | Bosutinib In Subjects With Renal Impairment | December 2010 | June 2012 |
| NCT01331291 | Completed | Phase 2 | Bosutinib in Adult Patients With Recurrent Glioblastoma | April 2011 | December 2014 |
| NCT01374139 | Completed | Phase 1 | Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | August 2011 | October 2011 |
| NCT01903733 | Completed | N/A | Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 | August 28, 2013 | June 5, 2020 |
| NCT02102633 | Completed | Phase 1 | Drug Interaction Study Between Bosutinib And Dabigatran | May 2014 | June 2014 |
| NCT02130557 | Completed | Phase 3 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | July 15, 2014 | April 17, 2020 |
| NCT02311998 | Completed | Phase 1/Phase 2 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | April 16, 2015 | March 23, 2022 |
| NCT02445742 | Completed | Phase 2 | CML Treated With Bosutinib After Relapse | May 2015 | June 27, 2019 |
| NCT02501330 | Completed | Safety And Efficacy Of Bosutinib | July 1, 2015 | February 28, 2024 | |
| NCT02546375 | Completed | A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | July 15, 2015 | January 16, 2017 | |
| NCT02638467 | Completed | Phase 2 | Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | November 2015 | February 2020 |
| NCT02810990 | Completed | Phase 2 | Bosutinib in Elderly Chronic Myeloid Leukemia | November 17, 2016 | June 22, 2022 |
| NCT01233869 | Completed | Phase 2 | Bosutinib For Autosomal Dominant Polycystic Kidney Disease | December 2010 | August 2014 |
| NCT00261846 | Completed | Phase 2 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | January 18, 2006 | August 6, 2015 |
| NCT00574873 | Completed | Phase 3 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | February 5, 2008 | May 27, 2015 |
| NCT00721474 | Completed | Phase 1 | Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects | September 2008 | September 2008 |
| NCT00725426 | Completed | Phase 1 | Effect of Rifampin on Bosutinib When Both Are Given to Healthy People | July 2008 | August 2008 |
| NCT00759837 | Completed | Phase 1 | Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | October 2008 | May 2009 |
| NCT03023319 | Completed | Phase 1 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | December 10, 2019 | May 10, 2022 |
| NCT03128411 | Completed | Phase 2 | Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | May 15, 2017 | March 4, 2021 |
| NCT03885830 | Completed | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | June 20, 2019 | June 15, 2022 | |
| NCT05032690 | Completed | Phase 1 | Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule | January 19, 2022 | June 25, 2022 |
| NCT05286528 | Completed | Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | November 18, 2020 | January 31, 2022 | |
| NCT05363488 | Completed | Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | October 8, 2021 | October 8, 2021 | |
| NCT02921477 | Enrolling by invitation | Phase 1 | Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias | September 2016 | December 31, 2025 |
| NCT06423911 | Not yet recruiting | Phase 3 | A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML | May 2024 | February 2026 |
| NCT03831776 | Recruiting | Phase 2 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis | March 25, 2019 | March 2028 |
| NCT04877522 | Recruiting | Phase 4 | Asciminib Roll-over Study | August 30, 2022 | August 30, 2027 |
| NCT03297606 | Recruiting | Phase 2 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | March 23, 2018 | January 31, 2027 |
| NCT02228382 | Terminated | Phase 4 | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | November 7, 2014 | October 13, 2020 |
| NCT02782403 | Terminated | Phase 1 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | March 20, 2017 | November 11, 2019 |
| NCT02906696 | Terminated | Phase 2 | Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure | October 28, 2016 | August 8, 2019 |
| NCT00793546 | Terminated | Phase 2 | Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer | February 2009 | June 2010 |
| NCT00959946 | Terminated | Phase 1/Phase 2 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | September 2009 | March 2011 |
| NCT00880009 | Terminated | Phase 2 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | July 30, 2009 | May 31, 2010 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Bcr-Abl
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Src
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- CML
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2014
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2012
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Bosulif